Transmyocardial Revascularization Market Size, Share, & Trends Analysis | Global | 2026-2032

Global Transmyocardial Revascularization Device Market Report to 2032

The global transmyocardial revascularization device market was valued at $7.5 million in 2025. It is expected to decrease at a compound annual growth rate (CAGR) of -6.2%, reaching $4.8 million by 2032.

This report covers the global market for transmyocardial revascularization (TMR) devices, including devices used to treat selected patients with severe angina who are not candidates for other revascularization procedures.

The analysis includes unit sales, average selling prices (ASPs), market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market demand is supported by positive clinical outcomes in selected patients and the role of TMR as an alternative for patients who cannot undergo PCI or CABG. However, physician awareness, competing procedures, limited training, and restricted access to capital equipment are expected to drive market decline.

Market Overview

The global transmyocardial revascularization device market includes devices used to treat patients with chronic, severe angina who are not suitable candidates for standard revascularization procedures.

TMR devices remain a niche therapy. They are primarily used in a small population of refractory angina patients who are not candidates for coronary artery bypass grafting, percutaneous coronary intervention, or other standard treatment options.

The market is expected to decline over the forecast period as less invasive transcatheter therapies continue to expand. These alternatives have increasingly cannibalized the small patient pool that may have previously been considered for TMR.

Despite this decline, TMR continues to serve a defined clinical role for patients with regions of ischemia that cannot be treated with PCI or CABG. This preserves a limited market base, but the overall role of TMR is expected to diminish further through 2032.

Market Drivers

Clinical Outcomes

Clinical outcomes remain one of the key drivers supporting continued use of TMR devices. Long-term follow-up from randomized, multi-center controlled clinical trials has demonstrated improved survival and significant reductions in angina.

These studies have also shown increased exercise duration in patients treated with TMR systems and medications compared with patients treated with medications alone.

Positive clinical results can help encourage physicians and patients to consider TMR procedures in selected cases. Although the market remains small, evidence of symptom improvement and quality-of-life benefit supports continued use among patients with limited treatment alternatives.

Alternative Treatment to PCI and CABG

Many patients with severe angina do not respond adequately to pharmacological treatment and require a procedural option. In many cases, these patients may be treated with PCI, with or without stenting, or CABG.

However, some patients with chronic, severe angina are not candidates for PCI or CABG. This may be due to prior failed procedures, diffuse coronary artery disease, distal stenosis, extremely small coronary arteries, or other clinical limitations.

These patients represent the primary target population for TMR. For patients with ischemic regions that cannot be treated with PCI or CABG, TMR may offer an alternative method to reduce symptoms and improve quality of life.

Niche Role in Refractory Angina

TMR continues to have a niche role in refractory angina treatment. This role is narrow, but it remains clinically relevant for patients who have exhausted more common treatment options.

Because these patients may not be eligible for traditional surgery or interventional therapy, treatment choices are limited. TMR may be considered when the clinical goal is symptom relief rather than direct restoration through conventional revascularization.

This niche indication helps preserve demand for TMR devices, even as the broader market declines. However, because the eligible patient base is small, this driver is not expected to offset the pressure from alternative procedures and limited adoption.

Market Limiters

Physician Awareness and Alternative Procedures

The TMR market has experienced limited growth due to the crowded field of treatment options available for angina. Many competing therapies are more familiar to physicians and are used more often in daily practice.

CABG and PCI procedures are common and are performed regularly by cardiovascular surgeons and interventional cardiologists. These procedures are more established in treatment pathways and are more familiar to physicians than TMR.

If treatment with TMR lasers remains outside the standard of care, physician awareness and interest will remain low. This is expected to result in continued stagnation and decline in market demand.

Limited Training and Access

Limited access to technology and training restricts the number of physicians who can perform and offer TMR therapy. The procedure requires specialized knowledge, training, and the availability of dedicated equipment.

TMR devices require the sale and installation of an expensive capital equipment base unit. This has discouraged many hospitals from incorporating TMR into their angina treatment programs.

Until there is renewed interest or incentive for physicians to train in TMR procedures, and for hospitals to purchase the required capital equipment, uptake will remain limited. This is one of the main reasons the market is expected to decline over the forecast period.

Cannibalization from Less Invasive Therapies

The rapid adoption of less invasive transcatheter therapies is further constraining TMR demand. As alternative interventions expand, fewer patients are likely to be considered for TMR.

This trend is especially important because the TMR patient pool is already small. Even modest cannibalization from newer therapies can have a noticeable impact on market value.

As physicians and hospitals continue to prioritize familiar, less invasive, and more widely available procedures, the already limited role of TMR is expected to diminish further through 2032.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by competitive share analysis and forecast assumptions.
• Device scope: The report covers transmyocardial revascularization devices used in the treatment of selected refractory angina patients who are not candidates for PCI or CABG.

Markets Covered and Segmentation

Transmyocardial Revascularization Device Market

This segment is captured as an appendix.

The report covers the global transmyocardial revascularization device market as a niche segment within cardiac surgery and revascularization technologies.

TMR devices are used to treat selected patients with chronic, severe angina who cannot be treated effectively with PCI or CABG. These patients may have diffuse coronary artery disease, distal stenosis, extremely small coronary arteries, or previous failed procedures.

The market is analyzed by market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.

The report evaluates TMR demand based on refractory angina patient eligibility, procedural alternatives, physician awareness, clinical evidence, capital equipment access, and forecast market decline.

This structure helps manufacturers, investors, and strategy teams understand why TMR remains a limited market and how alternative therapies are reshaping the long-term outlook for this segment.

Competitive Analysis

The global transmyocardial revascularization device market is highly niche and much smaller than most cardiac surgery device segments. Competitive activity is limited because TMR is not broadly adopted as a standard treatment pathway.

The market is shaped less by broad product competition and more by the availability of capital equipment, hospital willingness to support the procedure, and physician familiarity with TMR technology.

Because TMR requires dedicated equipment and specialized training, manufacturers face a difficult adoption environment. Hospitals may be hesitant to invest in capital equipment for a procedure with limited volume and a narrow patient base.

The market is also pressured by established revascularization approaches such as PCI and CABG, as well as newer transcatheter therapies. These alternatives are more familiar to physicians and continue to reduce the pool of patients considered for TMR.

As a result, the competitive landscape is expected to remain limited over the forecast period. Companies participating in the segment must rely on niche clinical use cases, existing installed systems, and continued treatment of patients who are not suitable for more common procedures.

Technology and Practice Trends

Niche Use in Refractory Angina

TMR remains focused on a small group of patients with refractory angina who cannot be treated with PCI or CABG.

This narrow clinical role is expected to continue, but it will not support broad market expansion.

Clinical Outcomes as a Support Factor

Positive outcomes from long-term clinical follow-up remain important for supporting continued use. Improved survival, reduced angina, and increased exercise duration can help justify use in selected patients.

However, this evidence has not been enough to make TMR a mainstream treatment.

Competition from PCI and CABG

PCI and CABG remain the dominant procedural options for many patients with severe angina. These procedures are more familiar to physicians and are performed far more often.

This limits awareness and interest in TMR.

Less Invasive Transcatheter Alternatives

Less invasive transcatheter therapies are increasingly cannibalizing the TMR patient pool. As these options expand, fewer patients are likely to be referred for TMR.

This trend is expected to continue limiting market value.

Capital Equipment Barriers

TMR requires expensive capital equipment, which creates a barrier for hospitals. Low procedural volume makes it difficult for many facilities to justify investment.

This limits access and slows adoption.

Limited Physician Training

Few physicians are trained to perform TMR procedures compared with PCI or CABG. Without renewed training interest, the market will remain constrained.

Training limitations are expected to keep the procedure outside routine treatment pathways.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global transmyocardial revascularization device market today, and how is it expected to change through 2032?
• Why is the TMR market expected to decline over the forecast period?
• What role does TMR play in treating refractory angina patients?
• Which patients are not candidates for PCI or CABG and may be considered for TMR?
• How do clinical outcomes support continued use in selected cases?
• Why do physician awareness and standard-of-care preferences limit adoption?
• How do capital equipment requirements restrict hospital access to TMR technology?
• How are less invasive transcatheter therapies cannibalizing the TMR patient pool?
• What factors are constraining unit sales and market value growth?
• How should suppliers evaluate the future of this niche cardiac surgery device segment?

The Global Transmyocardial Revascularization Device Market Report from iData Research answers these questions with device-level analysis, ASP data, market share insights, and forecasts through 2032. Use it to evaluate demand, understand niche revascularization trends, assess market decline, and support commercial planning in the global TMR device market.